This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Effects of Intracoronary Streptokinase and Intracoronary Nitroglycerin Infusion on Coronary Angiographic Patterns and Mortality in Patients with Acute Myocardial Infarction

List of authors.
  • K. Peter Rentrop, M.D.,
  • Frederick Feit, M.D.,
  • Heinrich Blanke, M.D.,
  • Peter Stecy, M.D.,
  • Richard Schneider, M.D.,
  • Mariano Rey, M.D.,
  • Steven Horowitz, M.D.,
  • Martin Goldman, M.D.,
  • Karl Karsch, M.D.,
  • Henry Meilman, M.D.,
  • Marc Cohen, M.D.,
  • Stephen Siegel, M.D.,
  • Joseph Sanger, M.D.,
  • James Slater, M.D.,
  • Richard Gorlin, M.D.,
  • Arthur Fox, M.D.,
  • Richard Fagerstrom, Ph.D.,
  • and W. Ford Calhoun, Ph.D.

Abstract

We randomly assigned patients with a clinical diagnosis of acute myocardial infarction to one of four treatment groups: intracoronary streptokinase, intracoronary nitroglycerin, intracoronary streptokinase and intracoronary nitroglycerin, or conventional therapy without initial angiography.

Of 124 patients 122 sustained acute myocardial infarction. Initial angiography revealed total occlusion of the coronary artery responsible for infarction in 67 per cent (61 of 91). Acute recanalization occurred in 74 per cent (32 of 43) of patients receiving streptokinase but in only 6 per cent (1 of 18) of patients treated with nitroglycerin alone (P<0.01).

At angiography of all four groups on Day 10 to 14 the vessel responsible for acute myocardial infarction was patent in 77 per cent (71 of 92) of patients; there was no difference among groups, indicating gradual, endogenous thrombolysis in patients not treated with streptokinase. Patients with subtotal obstruction initially had significant improvement in left ventricular function, significantly lower peak creatine kinase levels, and a trend toward lower mortality than patients with total occlusion initially.

Mortality at six months in patients receiving streptokinase (21 per cent, 13 of 62) did not differ significantly from that in patients not treated with streptokinase (10 per cent, 6 of 61). Additional studies will be necessary to assess treatment effects in the angiographic subsets identified by this trial. (N Engl J Med 1984; 311:1457–63.)

Funding and Disclosures

Supported in part by the Heart Research Foundation, the New York Cardiac Center, the Heineman Foundation, and the Thea Brothers Fund.

Presented in part at the 33rd Annual Scientific Session of the American College of Cardiology, Dallas, March 23–29, 1984.

The Mount Sinai School of Medicine–New York University School of Medicine Reperfusion Trial included the following participants: Principal Investigators — K. Peter Rentrop, M.D., Frederick Feit, M.D., and Richard Gorlin, M.D.; Trial Design — Thomas Chalmers, M.D., Harry Smith, Ph.D., Richard Gorlin, M.D., Frederick Feit, M.D., Arthur Fox, M.D., Louis Teichholtz, M.D., and K. Peter Rentrop, M.D.; Monitoring Committee — Thomas Chalmers, M.D., Sherman Kupfer, M.D., Richard Gorlin, M.D., Janet Wittes, Ph.D., and Judith Goldberg, Ph.D.; Clinical Units — Mount Sinai Hospital: K. Peter Rentrop, M.D., Heinrich Blanke, M.D., Steven Horowitz, M.D., Karl Karsch, M.D., Martin Goldman, M.D., Marc Cohen, M.D., Augusto Pichard, M.D., and Richard Gorlin, M.D.; Bellevue Hospital: Frederick Feit, M.D., Peter Stecy, M.D., Mariano Rey, M.D., Henry Meilman, M.D., Stephen Siegel, M.D., James Slater, M.D., Marc Ehrich, M.D., Mark Nachamie, M.D., Frank Politzer, M.D., William Cole, M.D., and Arthur Fox, M.D.; City Hospital at Elmhurst: Richard Schneider, M.D., Francis Lane, M.D., Hee Lee, M.D., and Jai Rhee, M.D.; and Bronx Veterans Administration: Pavol Schweitzer, M.D., and Eric Stern, M.D.; Data Center — Harry Smith, Ph.D., Ford Calhoun, Ph.D., Richard Fagerstrom, Ph.D., and James Holt, M.A.; Data Managers—Lucy Painter, B.S., Susan Hosat, M.S., Mary Ann Matheson, R.N., Sharon Napoli, R.N., Naomi Hill, R.N., and Harold Felton, P.A.;Nuclear Core Laboratory — Joseph Sanger, M.D., Steven Horowitz, M.D., and Stanley Goldsmith, M.D.; Electrocardiographic Core Laboratory — Mariano Rey, M.D., Mark Nachamie, M.D., Marc Ehrich, M.D., and Stephen Siegel, M.D.;Angiographic Core Laboratory — Heinrich Blanke, M.D., Frederick Feit, M.D., and K. Peter Rentrop, M.D.; Creatine Kinase Core Laboratory — Robert Litwak, M.D., and Barbara Handke.

Author Affiliations

From the Departments of Medicine, Mount Sinai School of Medicine and New York University School of Medicine. Address reprint requests to Dr. Rentrop at the Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.

Print Subscriber? Activate your online access.